-
How artificial intelligence solutions can design new TB drug therapies
Time of Update: 2021-02-15
With a shortage of new TB drugs, a software tool at the University of Michigan can predict how current drugs, including unlikely drug candidates, can combine new ways to create more effective treatments.
-
Jun Shengtai will present the htd1801 study data at the 2019 annual meeting of the American Association for the Study of Hepatology
Time of Update: 2021-02-15
Developed by the Junsantai team, HTD1801 is conducting Phase II clinical trials in the United States for non-alcoholic fatty hepatitis (NASH) and primary sclerotic bileitis (PSC).
Phase II clinical data are expected to be released in 2020.
-
Scientists have discovered the key factors that cause atherosclerosis
Time of Update: 2021-02-15
Based on the findings, researchers at Yale University and the Massachusetts Institute of Technology have launched VasoRX, a biotech company, to develop this targeted approach, using RNAi drugs from nanoparticles as a potential treatment for atherosclerosis in humans.
-
Studies have found that flu vaccines can reduce the risk of death in older patients
Time of Update: 2021-02-15
new study from Aohus University and Aohus University Hospital found that older patients who were admitted to intensive care units had a lower risk of death and bleeding from blood clots or brain bleeds if they were vaccinated against the flu.
-
New targets may solve the problem of chronic hepatitis recurrence
Time of Update: 2021-02-13
"We have reason to conclude that ifI16 molecules can serve as a new and important target to monitor and suppress long-term recurrence of chronic hepatitis." Recently, at the first Zijin Translational
-
A new treatment for type 2 diabetes
Time of Update: 2021-02-13
According to a new study by researchers at Will Cornell Medical and New York Presclin, fatty proteins produced in human fat help protect insulin secretion cells called pancreatic β cells from type 2 diabetes.
-
Accidental injury resulting in skull defects? The "brain-replenishing" material is better
Time of Update: 2021-02-13
On the morning of July 13th, the 3D printing and advanced cranial maxillofacial trauma repair-cum Tianfu Medical Exchange Summit Forum was held in Chengdu, Sichuan Province, and Professor Guan Junwen, Director of Neurosurgery at Huaxi Hospital of Sichuan University, introduced that the development of science and technology, the breakthrough of technical barriers to 3D printing, so that patients with brain injury benefit more.
-
Researchers will have new insights into retinal genetic code
Time of Update: 2021-02-13
Australian scientists have led the development of the world's most detailed map of human retinal genes and provide new insights that could help future research to prevent and treat blindness.
-
Significant progress! The combined use of three strategies results in a nearly 100% response rate to cancer treatment
Time of Update: 2021-02-12
In a new study, researchers from Massachusetts General Hospital, New Jersey State University and Rush University Medical Center found that combining three advanced strategies for treating malignant melanoma ---promole-targeted therapy, immune checkpoint blocking, and the use of lysomavirus--- could significantly improve outcomes.
-
Scientists have found hidden special estrogen-like estrogen in breast epithal cells
Time of Update: 2021-02-12
Now, researchers have found that nearly half of the intra-cavity mammary epithelial cells that do not express estrogen receptors actually express them at lower levels, and in this study, researchers have found that different parts of the estrogen receptor may play a different role in cancer-inducing tube breast cells, depending on the level of estrogen receptors in the cells, and that estrogen-dependent activity has more or less an effect on cell function.
-
Compounds that block latent HIV-1 reactivation were found
Time of Update: 2021-02-12
In a new study, researchers from the University of Pittsburgh in the United States identified compounds that block latent HIV-1 reactivation in human cell systems containing latent HIV-1.
-
Develop the first immunotherapy with the steady-state changes of the shear body! Baishi Meishi Guibao and Weishi subsidiary H3 reached a strategic joint:
Time of Update: 2021-02-12
BMS and Japanese drug company Eisai and H3 Biomedicine, a U.S. precision pharmaceutical research and development subsidiary, recently announced a multi-year research collaboration focused on assessing whether innovative therapies developed using H3's RNA cutting platform can provide a stronger response to cancer.
-
57% of patients achieved full remission of new treatment for urethroid skin cancer with positive results in Phase 3
Time of Update: 2021-02-12
UroGen Pharma announced that UGN-101, a non-surgical treatment for low-grade upper urethra cancer (LG UTUC), achieved positive top-line results in critical Phase 3 clinical trials, with 57 percent of patients achieving complete remission (CR).
-
Dual-functional immunotherapy! The FDA awarded Merck TGF-β/PD-L1 dual-target therapy M7824 to treat bile duct cancer orphans.
Time of Update: 2021-02-12
BTC treatment options are limited, the medium survival of late-stage patients is less than 1 year, the objective tumor mitigation rate for common chemotherapy is usually less than 10%, and the remission time is short.
-
Scientists have developed a new treatment for type 2 diabetes
Time of Update: 2021-02-12
Restoring insulin's function is a key to treating type 2 diabetes, and in a recent study published in the international journal Nature Metabolism, scientists from the University of Toulouse developed a new treatment strategy that uses a special enzyme called hormone-sensitive lipase (HSL), which may have beneficial effects on insulin activity when stimulating fat synthesis in fat cells.
-
The new artificial intelligence system is expected to accelerate research in the field of cancer
Time of Update: 2021-02-12
In a recent study published in the international journal Bioinformatics, scientists from the University of Cambridge developed a new AI system called LION LBD, which could help researchers conduct can
-
Bacteria in the gut can accurately reveal a person's true age
Time of Update: 2021-02-12
To find out how the gut microbiome changes over time, Alex Zhavoronkov, a longevity researcher at InSilico Medicine, an artificial intelligence startup based in Rockville, Md., and colleagues studied more than 3,600 samples of gut bacteria from 1,165 healthy people worldwide.
-
Stem cells to treat diabetes! I3C/Mitsubishi UFJ/Tokyo University of Technology collaborated on the use of iPSC to create a β pancreas:
Time of Update: 2021-02-12
Japanese pharmaceutical companies Daiichi Sankyo, Mitsubishi UFJ Capital Co., Ltd. and Tokyo Institute of Technology have jointly announced that they will launch an open and innovative study aimed at creating insulin-producing cells with induced erythrocyte stem cells (iPSCs) for regenerative medicine and cell therapy.
-
New metal catalysts increase the diversity of drug design
Time of Update: 2021-02-12
"It will allow drug developers to replace hydrogen atoms with oxygen atoms without having to start making new drugs from scratch." The team successfully catalyzed the oxidation reaction of 50 molecules using a new manganese catalyst, four of which are drug stents, with the potential to rapidly produce derivatives with different biological activities or metabolites she said.
-
Innovative therapies for fibrosis! Gilead and Scholar Rock reach strategic partnership to develop new TGF beta activation inhibitors:
Time of Update: 2021-02-12
U.S. pharmaceutical giants Gilead and Scholar Rock recently announced that they have entered into a strategic partnership to discover and develop highly specific conversion growth factor β (TGF beta) activation inhibitors for the treatment of fibrous diseases.
